Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
PHIO
$1.085
$
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Next Earnings
2026-02-25
Beta
0.941
Average Volume
Market Cap
Last Dividend
CIK
0001533040
ISIN
US71880W5013
CUSIP
71880W303
CEO
Robert J. Bitterman
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
5
IPO Date
2012-05-10
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday? | Phio Pharmaceuticals Corp. (NASDAQ: PHIO) stock is trading lower on Thursday; however, there is no news to justify the movement. The stock could possibly be down on profit-taking after the stock closed nearly 15% higher on Wednesday. | Benzinga | 2026-02-12 08:43:54 |
| Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients | Phio Pharmaceuticals Corp. (NASDAQ: PHIO) shares are up on Tuesday' as the company announced positive results from its Phase 1b clinical trial for its lead candidate, PH-762. | Benzinga | 2026-02-10 11:12:45 |
| Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients | Phio Pharmaceuticals shares rise after Phase 1b data shows strong safety and tumor clearance for its PH-762 skin cancer drug, with FDA talks planned in 2026. | Benzinga | 2026-02-10 11:12:45 |
| Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial | Maximum Dose Concentration in Final Cohort Yields 85% Pathological Response (6 of 7 Patients); Complete Response (100% Tumor Clearance) in 4 of 6 Responders No Serious Adverse Events or Dose-Limiting Toxicities Identified Across All 5 Dose Escalation Cohorts King of Prussia, Pennsylvania--(Newsfile Corp. - February 10, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that the Safety Monitoring Committee (SMC) has concluded its planned safety review for all patients treated with the INTASYL compound PH-762 in Phio's Phase 1b clinical trial. | Newsfile Corp | 2026-02-10 07:00:00 |
| Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference | Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ET King of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ. | Newsfile Corp | 2026-01-26 08:15:00 |
| Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial | Pathology data indicate 70% overall response rate for squamous cell carcinomas: 100% clearance in 10 out of 14 responders Favorable safety and tolerability at all dose escalations King of Prussia, Pennsylvania--(Newsfile Corp. - January 20, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today a summary of the pathology results and safety outcomes across all cohorts in its Phase 1b dose escalation clinical trial with the INTASYL compound PH-762 for the treatment of skin cancer. | Newsfile Corp | 2026-01-20 09:30:00 |
| Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026 | Registration Link for Phio's Presentation on Thursday, January 22 at 1:45 PM ET King of Prussia, Pennsylvania--(Newsfile Corp. - January 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. | Newsfile Corp | 2026-01-15 08:45:00 |
| Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762 | Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026 King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it has taken a major step forward in its drug development program for PH-762. | Newsfile Corp | 2025-12-23 08:45:00 |
| Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 | King of Prussia, Pennsylvania--(Newsfile Corp. - November 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today the completion of enrollment in its ongoing Phase 1b clinical trial of INTASYL siRNA PH-762. | Newsfile Corp | 2025-11-25 11:30:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2026-02-18 | 2026-02-18 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-13 | 2026-02-13 | View Filing |
| 8-K | 2026-02-10 | 2026-02-10 | View Filing |
| 4 | 2026-02-06 | 2026-02-06 | View Filing |
| 4 | 2026-02-06 | 2026-02-06 | View Filing |
| 4 | 2026-02-06 | 2026-02-06 | View Filing |
| 4 | 2026-02-06 | 2026-02-06 | View Filing |
| 4 | 2026-02-06 | 2026-02-06 | View Filing |
| 4 | 2026-02-06 | 2026-02-06 | View Filing |
| 8-K | 2026-01-20 | 2026-01-20 | View Filing |
| 4 | 2026-01-02 | 2026-01-02 | View Filing |
| 4 | 2025-12-29 | 2025-12-29 | View Filing |
| 8-K | 2025-12-23 | 2025-12-23 | View Filing |
| SC 13G/A | 2025-12-11 | 2025-12-11 | View Filing |
| 424B3 | 2025-12-04 | 2025-12-04 | View Filing |
| EFFECT | 2025-12-03 | 2025-12-04 | View Filing |
| 8-K | 2025-11-25 | 2025-11-25 | View Filing |
| SC 13G/A | 2025-11-24 | 2025-11-24 | View Filing |
| 4 | 2025-11-24 | 2025-11-24 | View Filing |
| S-3 | 2025-11-20 | 2025-11-20 | View Filing |
| 4 | 2025-11-19 | 2025-11-19 | View Filing |
| 10-Q | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-13 | 2025-11-13 | View Filing |
| D | 2025-11-12 | 2025-11-12 | View Filing |
| SC 13G/A | 2025-11-12 | 2025-11-12 | View Filing |
| SC 13G | 2025-11-10 | 2025-11-10 | View Filing |
| SC 13G/A | 2025-11-07 | 2025-11-07 | View Filing |
| SC 13G/A | 2025-11-06 | 2025-11-06 | View Filing |
| 8-K | 2025-11-06 | 2025-11-06 | View Filing |
| 8-K | 2025-11-03 | 2025-11-03 | View Filing |
| 8-K | 2025-10-31 | 2025-10-31 | View Filing |
| 4/A | 2025-09-15 | 2025-09-15 | View Filing |
| 8-K | 2025-09-15 | 2025-09-15 | View Filing |
| 4 | 2025-09-15 | 2025-09-15 | View Filing |
| 4 | 2025-09-15 | 2025-09-15 | View Filing |
| 4 | 2025-09-15 | 2025-09-15 | View Filing |
| 4 | 2025-09-15 | 2025-09-15 | View Filing |
| 4 | 2025-09-15 | 2025-09-15 | View Filing |
| 4 | 2025-09-15 | 2025-09-15 | View Filing |
| 4 | 2025-09-15 | 2025-09-15 | View Filing |
| S-8 | 2025-09-11 | 2025-09-11 | View Filing |
| 8-K | 2025-09-03 | 2025-09-03 | View Filing |
| DEFA14A | 2025-08-28 | 2025-08-28 | View Filing |
| 424B3 | 2025-08-27 | 2025-08-27 | View Filing |
| EFFECT | 2025-08-25 | 2025-08-25 | View Filing |
| 10-Q | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13G/A | 2025-08-07 | 2025-08-07 | View Filing |
| D | 2025-08-04 | 2025-08-04 | View Filing |
| 8-K | 2025-07-30 | 2025-07-30 | View Filing |
| ARS | 2025-07-30 | 2025-07-30 | View Filing |
| DEFA14A | 2025-07-30 | 2025-07-30 | View Filing |
| DEF 14A | 2025-07-30 | 2025-07-30 | View Filing |
| 8-K | 2025-07-25 | 2025-07-25 | View Filing |
| 8-K | 2025-07-07 | 2025-07-07 | View Filing |
| 8-K | 2025-06-26 | 2025-06-25 | View Filing |
| 3 | 2025-06-18 | 2025-06-18 | View Filing |
| 8-K | 2025-06-12 | 2025-06-12 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-06-10 | 2025-06-10 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-21 | 2025-05-21 | View Filing |
| 10-Q | 2025-05-15 | 2025-05-15 | View Filing |
| 8-K | 2025-05-15 | 2025-05-15 | View Filing |
| 8-K | 2025-05-07 | 2025-05-07 | View Filing |
| 8-K | 2025-04-22 | 2025-04-22 | View Filing |
| 8-K | 2025-04-09 | 2025-04-09 | View Filing |
| 10-K | 2025-03-31 | 2025-03-31 | View Filing |
| 8-K | 2025-03-31 | 2025-03-31 | View Filing |
| 3 | 2025-03-04 | 2025-03-04 | View Filing |
| 8-K | 2025-02-20 | 2025-02-20 | View Filing |
| SC 13G/A | 2025-02-07 | 2025-02-07 | View Filing |
| 424B3 | 2025-01-29 | 2025-01-29 | View Filing |
| EFFECT | 2025-01-29 | 2025-01-29 | View Filing |
| D | 2025-01-28 | 2025-01-28 | View Filing |
| D | 2025-01-28 | 2025-01-28 | View Filing |
| D | 2025-01-28 | 2025-01-28 | View Filing |
| SC 13G | 2025-01-23 | 2025-01-23 | View Filing |
| S-1 | 2025-01-21 | 2025-01-21 | View Filing |
| SC 13G | 2025-01-17 | 2025-01-17 | View Filing |
| 8-K | 2025-01-17 | 2025-01-17 | View Filing |
| 424B5 | 2025-01-17 | 2025-01-17 | View Filing |
| 8-K | 2025-01-15 | 2025-01-15 | View Filing |
| 424B5 | 2025-01-15 | 2025-01-15 | View Filing |
| 8-K | 2025-01-14 | 2025-01-14 | View Filing |
| 424B5 | 2025-01-14 | 2025-01-14 | View Filing |
| 8-K | 2025-01-13 | 2025-01-13 | View Filing |
| D | 2025-01-07 | 2025-01-07 | View Filing |
| D | 2025-01-03 | 2025-01-03 | View Filing |
| SC 13G | 2024-12-27 | 2024-12-27 | View Filing |
| 8-K | 2024-12-26 | 2024-12-26 | View Filing |
| SC 13G | 2024-12-26 | 2024-12-26 | View Filing |
| 424B5 | 2024-12-23 | 2024-12-23 | View Filing |
| 8-K | 2024-12-20 | 2024-12-20 | View Filing |
| 424B5 | 2024-12-20 | 2024-12-20 | View Filing |
| 8-K | 2024-12-19 | 2024-12-19 | View Filing |
| 10-Q | 2024-11-14 | 2024-11-14 | View Filing |
| 8-K | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-13 | 2024-11-13 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Adaptive Wave | 22.70% | 1 | 1 | 1.22 | 1.03 | 12.29 |
| Price Action Strategy | 17.05% | 1.94 | 4 | 1.38 | 1.43 | 6.64 |
| Bull Bias | 14.81% | 0.99 | 39 | 1.03 | 1.48 | 4.4 |
| xxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | x | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | x | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | x | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | x | xxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxx | xxxxxx% | x | xx | xxxx | xxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxx | xxx |